Oral VV116 versus placebo in patients with mild-to-moderate COVID-19 in China: a multicentre, double-blind, phase 3, randomised controlled study
Fan et al., The Lancet Infectious Diseases, doi:10.1016/S1473-3099(23)00577-7
https://c19early.org/fan3.html